EMBJ at 52-Week High in Stage 2 Uptrend with Full Trend Template Pass

EMBJ stock profile infographic with daily candles, 20, 50 and 150-day simple moving averages and volume, Stage 2 (Advancing), as of November 11, 2026 at 08:23 - CANSLIM Research
EMBJ closed at 82.50, sitting right at its 52-week high and holding above a rising 30-week moving average, which confirms an intact Stage 2 advancing trend. The stock passes all 8 trend template checks, with price more than 54 percent above its yearly low and the relative strength line near a three-month high. No base or VCP has formed given the stock is at highs, but the setup reads as a bullish, offensive posture with sentiment scoring 6 out of 10.

EMBJ   Daily · data to 2026-11-10 close · 20 SMA 50 SMA 150 SMA
Frozen at publication – this chart does not move. Open live chart on TradingView →

SECTORIndustrialsINDUSTRYAerospace & DefenseStage 2Weinstein stage
Data to US close: Tue 10 Nov 16:00 ET = Wed 11 Nov 05:00 HKTCreated: Wed 11 Nov 08:23 HKT = 19:23 ET

Inside the Full Report

  • 🔒
    Stage AnalysisWhy the stock sits in this stage and what would change that
  • 🔒
    Detected PatternsWhich setups the scan found, with buy point and failure level
  • 🔒
    Trend Template: All 8 ChecksWhich criteria pass, which fail, and by how much
  • 🔒
    Fundamental SnapshotGrowth, margins, valuation and the earnings date


Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. Figures come from the scanned result (as of November 11, 2026) and company filings; all estimates not explicitly sourced from the provided data are clearly labeled as such. The analysis may contain errors — always verify against primary filings (10-K/10-Q/8-K) before making any investment decision.

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.